TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED Ratings Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Börse Stuttgart
Equities
2TZ
CNE100000924
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.196 EUR | -2.27% |
|
-6.28% | +21.02% |
| 05-15 | Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Directorate and Committee Changes | CI |
| 04-30 | Tianjin Pharmaceutical's Q1 Profit, Revenue Fall 3% | MT |
Strengths
- The company returns high margins, thereby supporting business profitability.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +21.02% | 3.17B | - | ||
| +34.14% | 5.87B | B- | ||
| -30.04% | 3.71B | C+ | ||
| -22.68% | 2.71B | B- | ||
| -8.17% | 2.36B | - | D+ | |
| +42.02% | 1.89B | - | ||
| +45.22% | 1.5B | - | ||
| -12.58% | 1.44B | - | - | |
| +40.95% | 1.35B | - | ||
| -27.42% | 1.32B | - | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 600329 Stock
- 2TZ Stock
- Ratings Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
